Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 19/20 | 0.61 |
| ▸ | CTSL | P07711 | 3/20 | 0.49 |
| ▸ | CTSK | P43235 | 1/20 | 0.49 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | REN | P00797 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5761812 | 0.84 | CTSS (0.43) | CTSSCTSLCTSBREN | |
| SCHEMBL7363745 | 0.83 | CTSS (0.55) | CTSSCTSLCTSKREN | |
| SCHEMBL5757363 | 0.78 | CTSS (0.61) | CTSSCTSL | |
| SCHEMBL5758603 | 0.78 | CTSS (0.61) | CTSSCTSL | |
| SCHEMBL5757358 | 0.78 | CTSS (0.61) | CTSSCTSL | |
| SCHEMBL5758379 | 0.78 | CTSS (0.66) | CTSSCTSLCTSKCTSB | |
| SCHEMBL5761262 | 0.76 | CTSS (1.00) | CTSSCTSLCTSKCTSB | |
| SCHEMBL5760517 | 0.76 | CTSS (0.77) | CTSSCTSLCTSKCTSBREN | |
| SCHEMBL5756972 | 0.75 | CTSS (0.73) | CTSSCTSLCTSKCTSBREN | |
| SCHEMBL5760506 | 0.74 | CTSS (0.76) | CTSSCTSLCTSKCTSBREN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1204652-B1 | NOVEL SUCCINATE DERIVATIVE COMPOUNDS USEFUL AS CYSTEINE PROTEASE INHIBITORS | BOEHRINGER INGELHEIM PHARMA (US) | 2006-05-17 | — | — | EP | disclosed |
| US-6649642-B2 | Useful in the treatment of autoimmune and other cathepsin related diseases. | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-11-18 | — | — | US | disclosed |
| US-20030087939-A1 | NOVEL SUCCINATE DERIVATIVE COMPOUNDS USEFUL AS CYSTEINE PROTEASE INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2003-05-08 | — | — | US | disclosed |
| EP-1204652-A1 | NOVEL SUCCINATE DERIVATIVE COMPOUNDS USEFUL AS CYSTEINE PROTEASE INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2002-05-15 | — | — | EP | disclosed |
| US-20010041700-A1 | Novel succinate derivative compounds useful as cysteine protease inhibitors | BEKKALI YOUNES (US) | 2001-11-15 | — | — | US | disclosed |
| US-6313117-B1 | TREATING AUTOIMMUNE DISORDERS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2001-11-06 | — | — | US | disclosed |
| WO-2001009110-A1 | NOVEL SUCCINATE DERIVATIVE COMPOUNDS USEFUL AS CYSTEINE PROTEASE INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2001-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010041700-A1 | Novel succinate derivative compounds useful as cysteine protease inhibitors | SDHA, LONP1, SUCNR1 | CTSS 15/4885CTSL 56/4885CTSK 100/4885 |
| US-20030087939-A1 | NOVEL SUCCINATE DERIVATIVE COMPOUNDS USEFUL AS CYSTEINE PROTEASE INHIBITORS | SDHA, LONP1, SUCNR1 | CTSS 15/4885CTSL 56/4885CTSK 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.